From Inception to Clinical Testing

iPSC Cell Therapies

Cell therapy is a fast-growing and highly promising field of biomedical research that plays a crucial role in the development of novel therapeutics given its potential to provide functional cures.

While most current cell therapies focus on autologous approaches, an off-the-shelf allogenic approach based on induced pluripotent stem cells (iPSC) offers significant advantages compared to both autologous and donor-derived allogenic therapies.  

It is Evotec’s goal to provide safe, efficacious and highly cost-effective cell therapy products to large patient groups across a broad range of disease areas. To achieve that, Evotec has built a unique, industry-leading end-to-end platform to develop and manufacture off-the-shelf iPSC-based cell therapeutics, fully integrated under one roof.

Advantages of iPSC-based Approach

iPSC based cell therapy
  • Reduced complexity: Patient is not part of manufacturing process
  • Unlimited starting material
  • Clonal & high fidelity gene editing
  • Consistent quality of final product
  • On demand product availability to patients
  • Versatile: Single platform suitable to manufacture multiple cell types & diseases

End-to-end Platform Integrated Under One Roof

Evotec provides all relevant technologies, know-how, scientists and infrastructure to jump start and speed-up the development of a new class of cell therapies with the capacity to cure. This involves all steps from research to development up to clinical testing in patients of cell therapy product candidates. Thus, it comprises an end-to-end integrated process flow from project inception to the clinic, including cell differentiation, upscaling and GMP manufacturing.

Evotec's Integrated iPSC end-to-end Platform

Flexible Partnership & Collaboration Models

Evotec’s internal iPSC-based project candidate pipeline is one of the broadest in the industry and includes anti-tumor therapies, regenerative therapies to treat diabetes or heart failure, and immune-modulation therapies. Our platform also includes state-of-the-art gene editing and targeting technologies such as CAR (chimeric antigen receptor), TCR (t-cell receptor), and ICE (immune cell engager), and a GMP facility to manufacture product candidates for clinical development.

In line with Evotec’s mission “Together for Medicines that Matter”, we are seeking strategic partners to collaborate and co-develop our proprietary pipeline to treat multiple diseases. Our collaboration and partnership models are flexible and tailored to our partners’ needs - Reach out to us to discuss

Partnering model i PSC CT 230811

Contact Our Experts

Andreas Scheel

Andreas Scheel, PhD

EVP Head of Cell Therapy & Site Head Cologne

Logo Evotec white
Evotec has the right technologies & disease understanding to meet our partners' evolving needs: a comprehensive disease knowledge at the molecular level, cutting-edge technologies & platforms to translate this expertise into effective precision medicines.